

鴨病毒性肝炎疫苗之研發

製劑研究組
施雨華 助理研究員

摘要

鴨病毒性肝炎(Duck viral hepatitis;DVH)是發生在4週齡以內雛鴨的急性致死性疾病，以肝炎為主要病變。本所為控制DVH的感染，研發鴨病毒性肝炎主動免疫用疫苗以及被動免疫用抗體製劑，目的希望可以有效預防鴨病毒性肝炎之發生。104年度進行鴨病毒性肝炎疫苗的田間試驗。試驗結果顯示本疫苗安全性佳，且由效力試驗結果得知此疫苗於種鴨免疫後，於種蛋卵黃可以檢測到病毒中和抗體中和指數大於3.0以上(國家檢定標準)。鴨病毒性肝炎卵黃抗體製劑則申請評價以及試製一批送國家檢定。未來將可以供給農戶完整DVH防疫所需疫苗製劑，有效預防DVH發生。

Development of Duck Viral Hepatitis Vaccine

Yu-Hua Shih

Abstract

Duck viral hepatitis (DVH) is an acute fatal disease characterized by hepatitis, and occurs in ducklings under 4 weeks old. In order to control DVH, AHRI developed DVH active immunization vaccine and passive hyperserum to effectively prevent the occurrence of DVH. In 2015, we have conducted field trials of duck viral hepatitis vaccine. The results showed that this vaccine is both safe and efficacious, and the breed ducks' egg antibodies reach the national inspection standards ($NI > 3.0$) after immunization. In addition, the value of egg yolk antibody product against DVH had been assessed for technology transfer and produced one batch for national inspection. In conclusion, AHRI could provide complete biologics at preventing the occurrence of duck viral hepatitis in the future.